Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Masahiro Iseki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4954-3810; OpenAlex author ID A5080483009, A5158647747. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: 3 papers · 2026: 3 papers

Papers 20

  1. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  2. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Co-author DOI 10.1016/j.pan.2026.03.007↗
  3. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  4. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12328-025-02193-0↗
  5. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Co-author DOI 10.1097/mpa.0000000000002396↗
  6. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… Co-author DOI 10.1097/mpa.0000000000002503↗
  7. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.010↗
  8. Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment. Co-author DOI 10.1111/cas.15952↗
  9. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  10. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. Co-author PMID 36807179↗
  11. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2021.12.006↗
  12. Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. Co-author DOI 10.1016/j.surg.2022.09.002↗
  13. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  14. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  15. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  16. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  17. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1620/tjem.252.353↗
  18. Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct. Co-author DOI 10.1620/tjem.252.63↗
  19. [Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-… Co-author PMID 32157015↗
  20. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 19 shared papers, 2017–2026 · strength 2.87
  2. Masamichi Mizuma · 18 shared papers, 2017–2026 · strength 2.79
  3. Shuichi Aoki · 12 shared papers, 2021–2026 · strength 2.22
  4. Shimpei Maeda · 9 shared papers, 2017–2026 · strength 1.53
  5. Daisuke Douchi · 7 shared papers, 2023–2026 · strength 1.35
  6. Fuyuhiko Motoi · 10 shared papers, 2017–2026 · strength 1.28
  7. Kei Nakagawa · 10 shared papers, 2017–2025 · strength 1.28
  8. Mitsuhiro Shimura · 7 shared papers, 2017–2026 · strength 1.19
  9. Atsushi Masamune · 6 shared papers, 2019–2026 · strength 1.01
  10. Takanori Morikawa · 8 shared papers, 2017–2023 · strength 0.93
  11. Koetsu Inoue · 4 shared papers, 2023–2026 · strength 0.75
  12. Toru Furukawa · 3 shared papers, 2020–2026 · strength 0.58
  13. Koetsu Inoue · 3 shared papers, 2023–2025 · strength 0.50
  14. Kyohei Ariake · 4 shared papers, 2017–2026 · strength 0.49
  15. Tatsuo Hata · 5 shared papers, 2017–2021 · strength 0.45
  16. Tatsuyuki Takadate · 5 shared papers, 2017–2021 · strength 0.45
  17. Shingo Yoshimachi · 2 shared papers, 2025–2026 · strength 0.44
  18. Kei Kawaguchi · 4 shared papers, 2019–2022 · strength 0.42
  19. Naohiro Hirano · 2 shared papers, 2023–2026 · strength 0.40
  20. Takashi Kokumai · 2 shared papers, 2023–2025 · strength 0.36
  21. Yuichiro Umino · 2 shared papers, 2019–2026 · strength 0.32
  22. Taku Kano · 1 shared paper, 2025 · strength 0.25
  23. Nana Kimura · 1 shared paper, 2026 · strength 0.23
  24. Takamichi Igarashi · 1 shared paper, 2026 · strength 0.23
  25. Katsuhisa Hirano · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.